Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases
- PMID: 33616856
- DOI: 10.1007/s40620-021-00992-5
Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases
Abstract
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.
© 2021. Italian Society of Nephrology.
References
-
- Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836–2846 - DOI
-
- Joly BS, Coppo P, Veyradier A (2019) An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 12:383–395 - DOI
-
- Coppo P, Cuker A, George JN (2019) Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost 3:26–37 - DOI
-
- Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522 - DOI
-
- Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
